Form 4: Sight Sciences Director Brenda Larsen-Becker Receives Stock Grant

Director Brenda Larsen-Becker received 17,366 restricted stock units (RSUs) from Sight Sciences on June 6, 2024, under the company's Non-Employee Director Compensation Program.

Summary

• Brenda Larsen-Becker, a director at Sight Sciences, Inc., received a grant of 17,366 restricted stock units (RSUs) on June 6, 2024.
• The RSUs were granted under the Issuer's Non-Employee Director Compensation Program.
• Each RSU represents a contingent right to receive one share of Sight Sciences' common stock.
• The number of RSUs granted was determined by dividing $120,000 by the closing price of the common stock on the grant date.
• The RSUs will vest on the earlier of June 6, 2025, and the date of the Issuer's 2025 annual meeting of stockholders, contingent upon continued service as a director.
• Following the transaction, Larsen-Becker beneficially owns 48,088 shares, including common stock and RSUs.

Sentiment

Score: 7

Explanation: The document reflects a standard director compensation practice, which is generally viewed neutrally to positively as it aligns director and shareholder interests. The grant itself is a positive event for the director.

Positives

• The grant of RSUs aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service on the board of directors.

Future Outlook

The RSUs will vest on the earlier of June 6, 2025, and the date of the Issuer's 2025 annual meeting of stockholders, subject to the Reporting Person's continued service as a director on the Company's board of directors through such vesting date.

Industry Context

Director compensation through equity grants is a common practice in the industry to align the interests of directors with those of shareholders and incentivize long-term value creation.

Comparison to Industry Standards

• Equity compensation for board members is a standard practice across publicly traded companies, particularly in the technology and healthcare sectors.
• The size and structure of the RSU grant appear consistent with typical compensation packages for non-employee directors in similarly sized companies.
• Comparing Sight Sciences' director compensation to companies like Glaukos or Iridex, which also operate in the ophthalmology space, could provide further context.

Stakeholder Impact

• Shareholders may view the RSU grant as a positive sign, aligning director interests with long-term company performance.
• The director benefits from the equity grant, incentivizing continued service and contribution to the company's success.

Key Dates